Patents Issued in August 18, 2016
  • Publication number: 20160235790
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Application
    Filed: October 2, 2014
    Publication date: August 18, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Jodi P. GURNEY, Xiaokui ZHANG, Stacy HERB, Robert J. HARIRI
  • Publication number: 20160235791
    Abstract: This invention relates to a dermatological composition comprising, as an active ingredient, bacteria of at least one Stenotrophomonas strain and/or at least one Stenotrophomonas growth inducer, and the use thereof in the prevention and/or treatment of atopic dermatitis. This invention also relates to an in vitro method for prognosis and/or diagnosis of atopic dermatitis and a method for selecting a Stenotrophomonas growth inducer.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 18, 2016
    Inventors: Richard Martin, Sophie Seite, Anne Colonna
  • Publication number: 20160235792
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Application
    Filed: November 25, 2015
    Publication date: August 18, 2016
    Inventors: David Berry, Noubar B. Afeyan, Johanne Kaplan, Neal Gordon, Shaila Rahman
  • Publication number: 20160235793
    Abstract: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
    Type: Application
    Filed: February 19, 2016
    Publication date: August 18, 2016
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Stephen Howard Thorne
  • Publication number: 20160235794
    Abstract: The invention relates to a lipid extract of the seeds of passion fruit, Passiflora incarnata and/or Passiflora edulis, preferably P. edulis, characterised in that said lipid extract is an oil of passion fruit seeds concentrated in its unsaponifiable fraction, containing between 3 wt. % and 100 wt. % of unsaponifiable matter in relation to the total weight of the extract. The invention also relates to a method for preparing such an extract and to a composition comprising said extract, especially for the use thereof in a dermatological or pharmaceutical composition or as a food.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 18, 2016
    Applicant: LABORATOIRES EXPANSCIENCE
    Inventors: Sophie LECLERE-BIENFAIT, Stephanie BREDIF, Sebastien DEBROCK, Sebastien GARNIER
  • Publication number: 20160235795
    Abstract: There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.
    Type: Application
    Filed: February 8, 2016
    Publication date: August 18, 2016
    Inventors: Michel Maurice Jacques Lazdunski, Catherine Louise Heurteaux, David Picard
  • Publication number: 20160235796
    Abstract: A topical composition comprising from about 0.05% to about 10.0% by weight of Arnica oil, from about 5.0% to about 20.0% by weight of a notoginseng herb comprising dammarane-type ginsenosides, from about 0.05% to about 10% by weight of a compound comprising cyclopentasiloxane, dimethicone crosspolymer, dimethicone/vinyl dimethicone crosspolymer, dimethiconol, and a cosmetically acceptable aqueous carrier.
    Type: Application
    Filed: February 15, 2016
    Publication date: August 18, 2016
    Inventors: Peter Kennedy, Carolyn Shawn Murphy
  • Publication number: 20160235797
    Abstract: The present invention relates to extracts from Helichrysum odoratissimum for use in the prevention of and treatment of skin cancer. The invention also provides for pharmaceutical compositions containing the extract and to the use of medicaments containing the extract.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 18, 2016
    Inventors: Danielle Twilley, Namrita Lall
  • Publication number: 20160235798
    Abstract: Embodiments of the invention relate to a method for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof comprising administering to a patient in need thereof an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica. Optionally the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2. Further embodiments relate to use of extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica for the manufacture of a medicament for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 18, 2016
    Inventors: William Z. LEVINE, Gabriel Jay NUSSBAUM
  • Publication number: 20160235799
    Abstract: The present disclosure describes chemopreventative and/or chemotherapeutic compositions for inducing apoptosis in cancer cells which include kale and methods of inducing apoptosis in cancer cells utilizing the chemopreventative and/or chemotherapeutic compositions including kale.
    Type: Application
    Filed: February 10, 2016
    Publication date: August 18, 2016
    Inventors: Bilal Qizilbash, Elizabeth Brandon
  • Publication number: 20160235800
    Abstract: The present invention is directed to compositions for improving immune function and sensitivities to the natural and manmade environment that include ingredients from natural sources. It is further directed to methods of administering the compositions and kits containing the compositions. In a composition aspect, the composition is for regulating immune function and non-immune related sensitivities. It consists essentially of: 2 weight percent to 95 weight percent Psoralea; 2 weight percent to 95 weight percent Scutellaria; and 2 weight percent to 95 weight percent Xanthium. The Scutellaria portion may be replaced by Gardenia (in equal measure), or by a mixture of Scutellaria and Gardenia.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 18, 2016
    Applicant: Eclipta LLC
    Inventors: Edward Stephen MORRISSEY, Ruotao WANG
  • Publication number: 20160235801
    Abstract: A method and formulation for fluids, such as drinking water, containing plant phytochemicals are disclosed. Some plants can survive in water without a root system, and the formulation includes fluid, such as water, with one or more of the plants maintained in the fluid. Cold storage resulted in enhanced production and excretion of phytochemicals from the plants into the fluid, including bacosides and bacopasides. These phytochemicals have been shown to exhibit antioxidant properties, promote memory and provide additional health benefits, as well as replace bottled water or other fluids as a means to ensure proper hydration. The fluids are useful for enhancing alertness.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 18, 2016
    Inventors: Thomas Nadackal Thomas, Prem Mani Thomas
  • Publication number: 20160235802
    Abstract: A Chinese medicine capable of triggering lung adenocarcinoma cell autophagy mainly uses a polygala tenuifolia willd herb with a quantity depending on a patient's physical fitness and sickness conditions determined by a doctor, and capable of triggering a lung adenocarcionma cell autophagy (cracking) to achieve a treatment effect. Regardless of being taken as a powder or an extract, the medicine is capable of triggering the adenocarcionma cell autophagy (cracking) effect to achieve the treatment effect. The polygala tenuifolia willd applies a new protein transport mode as a target enzyme screening to successfully prove the effect of triggering lung adenocarcionma cell autophagy (cracking) for cancer treatment.
    Type: Application
    Filed: August 29, 2013
    Publication date: August 18, 2016
    Inventor: Kuan-chih CHOW
  • Publication number: 20160235803
    Abstract: The present disclosure provides a soft pastille containing turmeric extract as an active ingredient. The pastille is prepared using at least one gelling agent and at least one plasticizer in combination with pharmaceutically acceptable excipients, wherein the ratio of the gelling agent to the plasticizer is in a range of 1:2.5 to 1:3.3.
    Type: Application
    Filed: October 31, 2014
    Publication date: August 18, 2016
    Inventor: Jatin Vasant THAKKAR
  • Publication number: 20160235804
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicants: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Publication number: 20160235805
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 19, 2015
    Publication date: August 18, 2016
    Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
  • Publication number: 20160235806
    Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.
    Type: Application
    Filed: April 27, 2016
    Publication date: August 18, 2016
    Inventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
  • Publication number: 20160235807
    Abstract: This invention provides a method to prevent, control, and/or treat an inflammatory disease or disorder by administering at least one agonist of guanalyte cyclase receptor, or pharmaceutical compositions thereof, either alone or either concurrently or sequentially with another compound or an active agent used to treat the disease or disorder, and/or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Application
    Filed: October 9, 2014
    Publication date: August 18, 2016
    Inventor: Kunwar SHAILUBHAI
  • Publication number: 20160235808
    Abstract: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 18, 2016
    Inventors: Claudio Avila, Rafael Crabbe
  • Publication number: 20160235809
    Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 18, 2016
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Publication number: 20160235810
    Abstract: The invention relates to methods of treating metabolic conditions, including type 2 diabetes mellitus, by administering prolactin-inducible protein (PIP) or fusion proteins, analogs or variants of PIP with altered or truncated PIP sequence, site-specific mutants, or chemically modified mutants including pharmaceutical properties comprising the same.
    Type: Application
    Filed: October 16, 2014
    Publication date: August 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Avirup BOSE, Alokesh DUTTAROY
  • Publication number: 20160235811
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 18, 2016
    Inventors: Johan FROSTEGÅRD, Knut PETTERSSON
  • Publication number: 20160235812
    Abstract: In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents.
    Type: Application
    Filed: October 8, 2014
    Publication date: August 18, 2016
    Inventors: Suzanne Bruhn, Elizabeth Trehu, Mark Lupher
  • Publication number: 20160235813
    Abstract: A method and composition for reducing or alleviating inflammation in a subject is provided, including administering to the subject a therapeutically effective amount; of one or more isolated proteins respectively comprising an amino acid sequence set forth in SEQ ID NOS:1-31, or a biologically active fragment or variant thereof or combinations of these to thereby reduce or alleviate inflammation. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 18, 2016
    Inventors: Cinzia Cantacessi, Alex Loukas
  • Publication number: 20160235814
    Abstract: The invention generally relates to the field of biotechnology and medicine. It provides an agent, a pharmaceutical composition and a kit for treatment of autoimmune bullous diseases (AMDB). More specifically, the invention relates to the use of a soluble Fc gamma receptor for treating AMDB, and a pharmaceutical composition and a kit comprising said receptor. It further involves a method of treatment of AMDB.
    Type: Application
    Filed: October 16, 2013
    Publication date: August 18, 2016
    Applicant: SuppreMoI GmbH
    Inventors: Ralf Ludwig, Peter Sondermann, Dominik Ter Meer
  • Publication number: 20160235815
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 18, 2016
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN
  • Publication number: 20160235816
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Application
    Filed: July 17, 2014
    Publication date: August 18, 2016
    Inventors: Raymond A. CHAVEZ, Linda R. WATKINS, Robert LANDRY
  • Publication number: 20160235817
    Abstract: Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 18, 2016
    Inventor: Kathleen C. Somera-Molina
  • Publication number: 20160235818
    Abstract: The present invention refers to lixisenatide for use in pediatrics.
    Type: Application
    Filed: January 14, 2016
    Publication date: August 18, 2016
    Inventors: Karin Bergmann, Agnes Hincelin-Mery, Christelle Jan
  • Publication number: 20160235819
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John KLEINIG, Thomas R. TICE, Jay K. STAAS
  • Publication number: 20160235820
    Abstract: A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying at least one target region of the myocardium of the heart to be treated; and injecting a keratin-based material that travels to at least one target region to at least one of stiffen, restrain, or constrain the myocardial tissue of the target region. The material applied results in a physical modification of the mechanical properties, including stiffness, of the infarct tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation.
    Type: Application
    Filed: February 17, 2016
    Publication date: August 18, 2016
    Applicant: Cormend Technologies, LLC
    Inventor: John C. ANDRES
  • Publication number: 20160235821
    Abstract: The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1? (HIF-1?) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.
    Type: Application
    Filed: March 31, 2016
    Publication date: August 18, 2016
    Inventors: Mi Sun WON, Hyun Seung BAN, Bo Kyung KIM, Soon Woo NAM, Kyeong LEE, Young-Ju LEE, Hong-Sub LEE, Dong Uk KIM, Ki Cheol PARK, Joo-Young IM, Kyoung-Jin OH
  • Publication number: 20160235822
    Abstract: Provided are dietary supplements, formulations, kits and methods for administration to an individual with type II diabetes or at risk of developing type II diabetes. Provided herein are formulations, kits and methods useful for treating, preventing, supporting, controlling, restoring, and/or maintaining blood sugar levels in individuals with type II diabetes or at risk of developing the same. Also provided are formulations, kits and methods useful for reducing and/or eliminating requirement of ex-vivo insulin administration in an individual diagnosed with type II diabetes.
    Type: Application
    Filed: March 18, 2015
    Publication date: August 18, 2016
    Inventors: Michael Holstein, Eric Huntington
  • Publication number: 20160235823
    Abstract: Methods for reducing the environmental impact of animal waste are described. In particular embodiments, the methods comprise administering to an animal an enzyme, such as alkaline phosphatase, that is effective to reduce the amount of a detrimental compound, such as ammonia or phosphorous, that is present in or released from animal waste. Also provided is a method for increasing phosphorus digestion in an animal. Compositions suitable for use in such methods are also described.
    Type: Application
    Filed: April 29, 2016
    Publication date: August 18, 2016
    Inventors: David M. ANDERSON, Sergey PODKOVYROV, Yuefang HUANG, Kurt SCHUSTER, Jon Edward FERREL
  • Publication number: 20160235824
    Abstract: Compositions and methods for the modulation of hemostasis are disclosed.
    Type: Application
    Filed: November 3, 2014
    Publication date: August 18, 2016
    Applicant: The Children's Hospital Philadelphia
    Inventors: Rodney M Camire, Nabil K. Thalji
  • Publication number: 20160235825
    Abstract: Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Matthew J. Siegel, Bret Berner
  • Publication number: 20160235826
    Abstract: The present invention is based, at least in part, on the discovery that fragments of the histone deacetylase 4 (HDAC4) gene lacking the enzymatic domain promoted rod survival when electroporated into the retinas of a relevant mouse model of retinitis pigmentosa. Specifically, it has been discovered that only a small portion of the N-terminus of HDAC4 promotes survival of rod cells in rd1 mice. Accordingly, the present invention provides histone deacetylase 4 compositions and methods of use thereof for inhibiting neuronal cell death, e.g., retinal cell death.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 18, 2016
    Inventors: Constance L. Cepko, Bo Chen, Wenjun Xiong, Vedangi Sample
  • Publication number: 20160235827
    Abstract: Disclosed is the new, useful, and unexpected finding that immunization to placental endothelial cells stimulated with interferon gamma result in antibodies to the checkpoint inhibitor PD-L1. In one embodiment, the invention teaches the use of ValloVax™ to induce immunological hyperresponsiveness and reduction of costimulatory need for T cell activation. In another embodiment the invention teaches means of selecting placental populations for enhanced expression of PD-L1 in order to augment immunity towards checkpoint inhibitors.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 18, 2016
    Applicant: Batu Biologics, Inc.
    Inventors: Samuel C. Wagner, Thomas E. Ichim
  • Publication number: 20160235828
    Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.
    Type: Application
    Filed: October 20, 2014
    Publication date: August 18, 2016
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Satoshi FUKAYA, Toshihiro OSADA, Hiroshi WADA
  • Publication number: 20160235829
    Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
    Type: Application
    Filed: May 4, 2016
    Publication date: August 18, 2016
    Inventor: Joseph John BINDER
  • Publication number: 20160235830
    Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 18, 2016
    Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
  • Publication number: 20160235831
    Abstract: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 18, 2016
    Applicant: Sanofi Pasteur SA
    Inventors: Pierre Chouvenc, Alain Francon
  • Publication number: 20160235832
    Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
    Type: Application
    Filed: October 15, 2014
    Publication date: August 18, 2016
    Inventors: Ya-Ping Ko, Magnus Hook, Suzan HM Rooijakkers, Mary Beth Browning
  • Publication number: 20160235833
    Abstract: Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
    Type: Application
    Filed: January 11, 2016
    Publication date: August 18, 2016
    Inventors: Dan M. Granoff, Peter T. Beernink
  • Publication number: 20160235834
    Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wail, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.
    Type: Application
    Filed: October 13, 2014
    Publication date: August 18, 2016
    Inventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pèrez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
  • Publication number: 20160235835
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Application
    Filed: January 27, 2016
    Publication date: August 18, 2016
    Applicant: Seqirus UK Limited
    Inventors: Mario CONTORNI, Derek O'HAGAN, Nicola GROTH
  • Publication number: 20160235836
    Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.
    Type: Application
    Filed: September 30, 2014
    Publication date: August 18, 2016
    Applicants: Los Alamos National Security, LC/TAS, Duke University, Dana-Farber Cancer Institute
    Inventors: Bette T.M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
  • Publication number: 20160235837
    Abstract: The present invention provides an isolated or synthesized protein fragment or peptide comprising at least one peptide sequence that is at least 50% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 80% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 46% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 53% homologous with at least one Replikin peptide sequence.
    Type: Application
    Filed: October 16, 2014
    Publication date: August 18, 2016
    Inventors: Samuel BOGOCH, Elenore S. BOGOCH, Anne-Elenore Bogoch BORSANYI, Samuel Winston BOGOCH
  • Publication number: 20160235838
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Application
    Filed: October 2, 2014
    Publication date: August 18, 2016
    Inventors: David Weiner, Daniel Villareal, Mathew Morrov, Jian Yan
  • Publication number: 20160235839
    Abstract: Compositions comprising calcium fluoride composites comprising Ca, F, and an organic molecule are provided, as are methods for their use.
    Type: Application
    Filed: October 23, 2014
    Publication date: August 18, 2016
    Applicant: GlaxoSmithKline Biologicals, S.A.
    Inventor: Vincent Vande Velde